2,200
Participants
Start Date
July 1, 2020
Primary Completion Date
June 30, 2021
Study Completion Date
June 30, 2022
Seroprevalence of SARS-CoV-2 infection in patients with HIV infection
On inclusion, after information and collection of the non-objection, a blood sample (D0) will be taken during the assessment of the HIV infection (no unplanned sample will be taken) and a control to determine the appearance or the Persistence of antibodies will be made at M6 and M12 always as part of the assessment of HIV infection.
Valérie POURCHER, Paris
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
OTHER